Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlphaMedix in Somatostatin Receptor Expressing Neuroendocrine Tumors
NCT05153772Phase 2Active, not recruiting
- Sponsor
- Orano Med
- Start
- Dec 2021
- Primary completion
- Apr 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of Dotamtate Pb-212 in Neuroendocrine Neoplasm (NEN), sponsored by Orano Med. Started Dec 2021; status: active, not recruiting.
02
Drugs
Dotamtate Pb-212
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05153772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153772.